CEO Interview

Bioprinted Mini-Heart Addresses a $5B+ Market Opportunity

BIOLIFE4D Corp. is a pioneering, development stage biotech company that plans to leverage current advances in life sciences and cardiac tissue engineering to build human hearts first for cardiotoxicity testing and then potentially for suitable implantation.

We plan to strategically position ourselves at the center of an unprecedented convergence of regenerative medicine, stem cell biology, additive manufacturing (3D printing), and computing technology – all having reached a level of maturity where we believe that commercially viable bioprinting solutions can be created through optimization, not invention. With BIOLIFE4D, a patient-specific, fully functioning heart may be created through 3D bioprinting using the patient’s own cells, potentially eliminating the challenges of organ rejection and long donor waiting lists that plague existing organ transplant methods.

BIOLIFE4D is committed to perfecting the technology to make viable organ repair and replacement an accessible and affordable reality.

BIOLIFE4D